Certified by Founder
Lodge
Alveus Therapeutics Inc
start up
United States
- Philadelphia, Pennsylvania
- 09/01/2026
- Series A
- $160,000,000
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.
- Industry Biotechnology Research
- Website https://alveustx.com/
- LinkedIn https://www.linkedin.com/company/alveus-therapeutics/
Vector π» | $10,000,000 | (May 14, 2026)
Avant Genomics | $3,000,000 | (May 14, 2026)
Data Mission | $1,000,000 | (May 14, 2026)
SwishX | $2,200,000 | (May 14, 2026)
Dolfin | $2,460,580 | (May 14, 2026)
4AM | $4,000,000 | (May 13, 2026)
Sedivention - Freezing the hunger feeling | $3,402,541 | (May 13, 2026)
Meatly | $14,074,996 | (May 13, 2026)
NanoStruct GmbH | $3,050,853 | (May 13, 2026)
Adfin | $18,000,000 | (May 13, 2026)
Boundary | $2,000,000 | (May 13, 2026)
Knit Health | $11,600,000 | (May 13, 2026)